

NOMINATIONS AND NEEDS ANALYSIS

Estimated number of Remdesivir vials: from October 2020 until March 2021

Please return by **19/08/2020** to

5.1.2e

@ec.euro

Country		
Purchasing entity (Contracting authority for the purpose of the signature of the framework contract)		
Person representing the purchasing entity for the signature of the contract		
Place of delivery (town/province or "multiple locations")		
Competent courts (town)		
Contact person for the performance of the contract (to be used in Article I.8 of the contract) (Name, organization, position, phone, e-mail)		

Nomination for the Specific Procurement Procedure Steering Committee (SPPSC)¹ - please complete if not Member

Alternate member

¹ Cf. Article 5(3) of the Draft Rules of Procedure of the SPPSC

3 AND NEEDS ANALYSIS

pa.eu

Europe Steering Committee (SPPSC)¹ - please complete if not

Background:

We would like to ask for your assistance in providing future estimates for the following:

- to gather Remdesivir supply needs during the period October 2020 - March 2021 (with the assumption that is

Please Note: 5.1.1c

- Remdesivir is authorized for adults and adolescents (age 12 and older, body weight over 40 kg) with pneumo therefore we are asking for the total number of hospitalized patients expected on a monthly basis

- Please provide your estimate of patients (%) not requiring oxygen, requiring oxygen, and those requiring mech

- Please provide your estimates of:

Patients requiring 10 days treatment with Remdesivir – ventilated or ECMO

Patients requiring 5 days treatment with Remdesivir – all the others

We would like to thank you for your support in completing the requested data for your country in the Data In

not possible to do stockpiling)

nia requiring supplementary oxygen i.e. hospitalized patients -

anical ventilation and/or extracorporeal membrane oxygenation (ECMO)

put Tab (please enter data in the grey shaded cells).

Member State:

Estimated number of future Covid-19 related hospitalizations & potential requirement for Remdes

Absolute Numbers	Total New Patient cases of Covid-19 hospitalized (incidence)	% Hospitalized patients NOT Requiring Oxygen	% Hospitalized patients Requiring Oxygen	% Hospitalized patients requiring invasive mechanical ventilation +/- ECMO
Oct-20	1217	0%	100%	25%
Nov-20	1217	0%	100%	25%
dec-20	1217	0%	100%	25%
Jan-21	1217	0%	100%	25%
feb-21	1217	0%	100%	25%
Mar-21	1217	0%	100%	25%
Total	7,300			

ECMO: extracorporeal membrane oxygenation

Vials

PRODUCT	Needs for the duration of the contract, i.e. from October 2020 until March 2021(number of vials)
Remdesivir, 100 mg powder for concentrate for	5.1.2b

² EMA conditional marketing authorisation (EU/1/20/1459/002)

ivir: **October 2020- March 2021** (no stockpiling)

Patients requiring 10 days treatment – ventilated or ECMO	Patients requiring 5 days treatment – all the others
304	912.5
304	912.5
304	912.5
304	912.5
304	912.5
304	912.5
1,825	5,475

11

6

(number of vials) (should there be a possibility to extend the contract duration beyond end	Additional remarks
5.1.2b	

Categorie	Aantal patiënten	Bron
Totaal aantal gehospitaliseerde COVID patiënten t/m 18/9	11,401	https://www.rivm.nl/coronavirus
Totaal aantal COVID patiënten op IC t/m 18/9	3,006	https://www.stichting-nice.nl/
	Aandeel IC patiënten	
	26%	

-covid-19/grafieken